Trial Information - Phase II
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer
Disease Specifics: (NSCLC)
Protocol ID: VS-6766-202
Sponsor: Verastem, Inc
Status: STUDY ON HOLD
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
